lipid mediated transfection reagent  (Roche)


Bioz Verified Symbol Roche is a verified supplier
Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88

    Structured Review

    Roche lipid mediated transfection reagent
    Role of phosphoinositide 3-kinase (PI3K) and p38 kinase inhibition on human oestrogen receptor (hER) β splice variant-mediated repression of human AVP (hAVP) promoter activity. SK-N-SH cells were transiently transfected with 0.15 μ g of hAVP-luciferase reporter construct and 0.15 μ g of an expression vector containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post <t>transfection,</t> cells were treated with vehicle (0.001% EtOH) or 100 nM 17 β -oestradiol (E 2 ), (A) 10 μ M LY 294002 or (B) 10 μ M SB202190 and 100 nM ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector, vehicle-treated controls. *P
    Lipid Mediated Transfection Reagent, supplied by Roche, used in various techniques. Bioz Stars score: 88/100, based on 1943 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lipid mediated transfection reagent/product/Roche
    Average 88 stars, based on 1943 article reviews
    Price from $9.99 to $1999.99
    lipid mediated transfection reagent - by Bioz Stars, 2020-09
    88/100 stars

    Images

    1) Product Images from "Characterisation of Human Oestrogen Receptor beta (ERβ) Splice Variants in Neuronal Cells"

    Article Title: Characterisation of Human Oestrogen Receptor beta (ERβ) Splice Variants in Neuronal Cells

    Journal: Journal of neuroendocrinology

    doi: 10.1111/j.1365-2826.2012.02337.x

    Role of phosphoinositide 3-kinase (PI3K) and p38 kinase inhibition on human oestrogen receptor (hER) β splice variant-mediated repression of human AVP (hAVP) promoter activity. SK-N-SH cells were transiently transfected with 0.15 μ g of hAVP-luciferase reporter construct and 0.15 μ g of an expression vector containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH) or 100 nM 17 β -oestradiol (E 2 ), (A) 10 μ M LY 294002 or (B) 10 μ M SB202190 and 100 nM ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector, vehicle-treated controls. *P
    Figure Legend Snippet: Role of phosphoinositide 3-kinase (PI3K) and p38 kinase inhibition on human oestrogen receptor (hER) β splice variant-mediated repression of human AVP (hAVP) promoter activity. SK-N-SH cells were transiently transfected with 0.15 μ g of hAVP-luciferase reporter construct and 0.15 μ g of an expression vector containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH) or 100 nM 17 β -oestradiol (E 2 ), (A) 10 μ M LY 294002 or (B) 10 μ M SB202190 and 100 nM ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector, vehicle-treated controls. *P

    Techniques Used: Inhibition, Variant Assay, Activity Assay, Transfection, Luciferase, Construct, Expressing, Plasmid Preparation

    Effects of 17 β -oestradiol (E 2 ), 17 β -diol (3 β -diol) and ICI 182 780 on human oestrogen receptor (hER) β splice variant-mediated arginine vasopressin (AVP) promoter activity before and after deletion of an activator protein-1 (AP-1) site. SK-N-SH cells were transiently transfected with 0.15 μ g of (A) human AVP (hAVP)-luciferase or (B) hAVPΔ611 – 604-luciferase reporter constructs and 0.15 μ g of expression vectors containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH), 100 nM E 2 , 3 β -diol or ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector, vehicle-treated controls. *P
    Figure Legend Snippet: Effects of 17 β -oestradiol (E 2 ), 17 β -diol (3 β -diol) and ICI 182 780 on human oestrogen receptor (hER) β splice variant-mediated arginine vasopressin (AVP) promoter activity before and after deletion of an activator protein-1 (AP-1) site. SK-N-SH cells were transiently transfected with 0.15 μ g of (A) human AVP (hAVP)-luciferase or (B) hAVPΔ611 – 604-luciferase reporter constructs and 0.15 μ g of expression vectors containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH), 100 nM E 2 , 3 β -diol or ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector, vehicle-treated controls. *P

    Techniques Used: Variant Assay, Activity Assay, Transfection, Luciferase, Construct, Expressing, Plasmid Preparation

    Effects of 17 β -oestradiol (E 2 ), 17 β -diol (3 β -diol) and ICI 182 780 on human oestrogen receptor (hER) β splice variant-mediated oestrogen response element (ERE) and activator protein-1 (AP-1) promoter activity. HT-22 cells were transiently transfected with 0.15 μ g of (A) 2x-ERE- or (B) AP-1-luciferase reporter constructs and 0.15 μ g of expression vectors containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH), 100 nM of E 2 , 3 β -diol or ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector controls. *P
    Figure Legend Snippet: Effects of 17 β -oestradiol (E 2 ), 17 β -diol (3 β -diol) and ICI 182 780 on human oestrogen receptor (hER) β splice variant-mediated oestrogen response element (ERE) and activator protein-1 (AP-1) promoter activity. HT-22 cells were transiently transfected with 0.15 μ g of (A) 2x-ERE- or (B) AP-1-luciferase reporter constructs and 0.15 μ g of expression vectors containing hER β 1, hER β 2, hER β 4 or hER β 5. Twenty-four hours post transfection, cells were treated with vehicle (0.001% EtOH), 100 nM of E 2 , 3 β -diol or ICI 182 780 for 12 h. Data represent the percentage change in relative light units compared to empty vector controls. *P

    Techniques Used: Variant Assay, Activity Assay, Transfection, Luciferase, Construct, Expressing, Plasmid Preparation

    2) Product Images from "Mouse Lymphoid Cell Line Selected To Have High Immunoglobulin Promoter Activity"

    Article Title: Mouse Lymphoid Cell Line Selected To Have High Immunoglobulin Promoter Activity

    Journal: Molecular and Cellular Biology

    doi:

    Transfection characteristics of the selected cell lines. (A) High-GFP-expressing cells from four rounds of FACS were single-cell cloned and transiently transfected with pGL3 containing four different promoters (H2B-59 + 1, IgH-154 + 35, B29-164 + 32, and mb-1-252 + 48). Cell line 2017, the parental clone 2017-IgH-GFP no. 9, and 70Z/3 were also transfected. The histone H2B promoter was used as a control. pCMV-βGal was cotransfected, and the luciferase/β-Gal ratios for the H2B construct were normalized to 1. The dark bars depict Ig promoter activity. Shaded bars are B29 and mb-1. Lipid-mediated transfection reagents were used. (B) Selected high-GFP cell lines 70Z/3 and 2017 and parent line 2017-IgH-GFP no. 9 were transiently transfected with either the 17.2.25 promoter (gray bars) or the V H 186.2 promoter with the IgH intronic enhancer upstream (white bars). pCMV-βGal was cotransfected, and luciferase/β-Gal ratios are depicted on the y axis. Lipid-mediated transfection reagents were used. (C) Selected cell lines m4, h3, and 70Z/3, and the parental cell line 2017-IgH-GFP no. 9 were transiently transfected with either IgH-154 + 35 (gray bars) or the same construct in which the intronic enhancer had been inserted (white bars) (see Materials and Methods). Lipid-mediated transfection reagents were used. pCMV-βGal was cotransfected as an internal control. Experiments were performed in triplicate, and error bars denote standard deviations. (D) Scanning promoter mutants were transiently transfected into either the parent cell line 2017-IgH-GFP no. 9 (gray bars) or the high-GFP-selected cell line m4 (white bars). Lipid-mediated transfection reagents were used. pCMV-βGal was cotransfected, and luciferase/β-Gal ratios are depicted on the y axis.
    Figure Legend Snippet: Transfection characteristics of the selected cell lines. (A) High-GFP-expressing cells from four rounds of FACS were single-cell cloned and transiently transfected with pGL3 containing four different promoters (H2B-59 + 1, IgH-154 + 35, B29-164 + 32, and mb-1-252 + 48). Cell line 2017, the parental clone 2017-IgH-GFP no. 9, and 70Z/3 were also transfected. The histone H2B promoter was used as a control. pCMV-βGal was cotransfected, and the luciferase/β-Gal ratios for the H2B construct were normalized to 1. The dark bars depict Ig promoter activity. Shaded bars are B29 and mb-1. Lipid-mediated transfection reagents were used. (B) Selected high-GFP cell lines 70Z/3 and 2017 and parent line 2017-IgH-GFP no. 9 were transiently transfected with either the 17.2.25 promoter (gray bars) or the V H 186.2 promoter with the IgH intronic enhancer upstream (white bars). pCMV-βGal was cotransfected, and luciferase/β-Gal ratios are depicted on the y axis. Lipid-mediated transfection reagents were used. (C) Selected cell lines m4, h3, and 70Z/3, and the parental cell line 2017-IgH-GFP no. 9 were transiently transfected with either IgH-154 + 35 (gray bars) or the same construct in which the intronic enhancer had been inserted (white bars) (see Materials and Methods). Lipid-mediated transfection reagents were used. pCMV-βGal was cotransfected as an internal control. Experiments were performed in triplicate, and error bars denote standard deviations. (D) Scanning promoter mutants were transiently transfected into either the parent cell line 2017-IgH-GFP no. 9 (gray bars) or the high-GFP-selected cell line m4 (white bars). Lipid-mediated transfection reagents were used. pCMV-βGal was cotransfected, and luciferase/β-Gal ratios are depicted on the y axis.

    Techniques Used: Transfection, Expressing, FACS, Clone Assay, Luciferase, Construct, Activity Assay

    (A) Cell lines BJA-B, M12, 70Z/3, θ4b, p5424, 2017, and EL-4 were transfected with either the pGL3 backbone (white bars) or IgH-luciferase promoter constructs containing (IgH-154 + 35) (light gray bars) or lacking (IgH-154 + 1) (dark gray bars) the sequences from the transcription initiation site to +35. pCMV-βGal was cotransfected as an internal control. Transfections were performed by electroporation. The luciferase/β-Gal activity ratio is depicted on the y axis. Averages from three replicate experiments are shown. Error bars denote standard deviations. (B) Promoter constructs containing 3-bp mutants spanning the transcription initiation site were electroporated into either the B-cell line BJA-B (white bars) or the nonlymphoid cell line WERI-27 (dark gray bars). The construct name is shown to the right of the sequence for that construct. The full-length (+35) and deletion (+1) constructs were included as controls. pCMV-βGal was cotransfected, and the luciferase/β-Gal activity ratio is shown on the x ). pCMV-βGal was cotransfected as an internal control. pUC18 was used to equalize the mass of the amount of DNA transfected. Transfections were performed by electroporation. The luciferase/β-Gal activity ratio is depicted on the y axis. Error bars denote standard deviations.
    Figure Legend Snippet: (A) Cell lines BJA-B, M12, 70Z/3, θ4b, p5424, 2017, and EL-4 were transfected with either the pGL3 backbone (white bars) or IgH-luciferase promoter constructs containing (IgH-154 + 35) (light gray bars) or lacking (IgH-154 + 1) (dark gray bars) the sequences from the transcription initiation site to +35. pCMV-βGal was cotransfected as an internal control. Transfections were performed by electroporation. The luciferase/β-Gal activity ratio is depicted on the y axis. Averages from three replicate experiments are shown. Error bars denote standard deviations. (B) Promoter constructs containing 3-bp mutants spanning the transcription initiation site were electroporated into either the B-cell line BJA-B (white bars) or the nonlymphoid cell line WERI-27 (dark gray bars). The construct name is shown to the right of the sequence for that construct. The full-length (+35) and deletion (+1) constructs were included as controls. pCMV-βGal was cotransfected, and the luciferase/β-Gal activity ratio is shown on the x ). pCMV-βGal was cotransfected as an internal control. pUC18 was used to equalize the mass of the amount of DNA transfected. Transfections were performed by electroporation. The luciferase/β-Gal activity ratio is depicted on the y axis. Error bars denote standard deviations.

    Techniques Used: Transfection, Luciferase, Construct, Electroporation, Activity Assay, Sequencing

    3) Product Images from "Differential Fibroblast Growth Factor 8 (FGF8)-Mediated Autoregulation of Its Cognate Receptors, Fgfr1 and Fgfr3, in Neuronal Cell Lines"

    Article Title: Differential Fibroblast Growth Factor 8 (FGF8)-Mediated Autoregulation of Its Cognate Receptors, Fgfr1 and Fgfr3, in Neuronal Cell Lines

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0010143

    Effects of FGF8b on GnRH promoter activity. Transient transfection of GT1-7 cells with 0.15 µg/well of mouse full-length GnRH-luciferase reporter construct. Following transfection, cells were treated with vehicle, FGF8b (50 ng/ml), PD173074 (100 nM), or FGF8b + PD173074 for 8 hours. Data are represented as mean percent change in RLU's from vehicle-treated controls ± SEM. Dissimilar letters indicate statistically significant difference among groups, P
    Figure Legend Snippet: Effects of FGF8b on GnRH promoter activity. Transient transfection of GT1-7 cells with 0.15 µg/well of mouse full-length GnRH-luciferase reporter construct. Following transfection, cells were treated with vehicle, FGF8b (50 ng/ml), PD173074 (100 nM), or FGF8b + PD173074 for 8 hours. Data are represented as mean percent change in RLU's from vehicle-treated controls ± SEM. Dissimilar letters indicate statistically significant difference among groups, P

    Techniques Used: Activity Assay, Transfection, Luciferase, Construct

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Roche lipid mediated transfection reagent
    Lipid Mediated Transfection Reagent, supplied by Roche, used in various techniques. Bioz Stars score: 88/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lipid mediated transfection reagent/product/Roche
    Average 88 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    lipid mediated transfection reagent - by Bioz Stars, 2020-09
    88/100 stars
      Buy from Supplier

    85
    Roche fugene6 lipid mediated transfection reagent
    Fugene6 Lipid Mediated Transfection Reagent, supplied by Roche, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fugene6 lipid mediated transfection reagent/product/Roche
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fugene6 lipid mediated transfection reagent - by Bioz Stars, 2020-09
    85/100 stars
      Buy from Supplier

    Image Search Results